Study Design:Systematic review.Objectives:The objective of this systematic review was to answer 2 key questions: (1)
What is the clinical presentation and probability of symptomatic improvement
following treatment for patients with renal cell carcinoma (RCC) of the
spine? (2) What is the overall survival of patients diagnosed with spinal
metastases from RCC?Methods:A literature review was performed to identify articles that reported on
survival, clinical outcomes, and/or prognostic factors in the RCC population
with spinal metastases from 1986 to 2016.Results:Forty-eight articles (807 patients) were included. The Fuhrman Nuclear Grade
has been significantly associated with survival in previous studies but was
underpowered in the current study. The Memorial Sloan-Kettering Cancer
Center Score (MSKCC/Motzer) was also underpowered in the current study. From
the time of spinal metastasis, the mean and median survival for patients
with previously diagnosed primary RCC was 8.75 and 11.7 months,
respectively, whereas synchronously diagnosed patients (primary RCC and
spinal metastasis) had a mean and median survival of 6.75 and 11 months,
respectively. Patients with a “low” (0-8), “intermediate” (9-11), or “high”
(12-15) revised Tokuhashi score at initial presentation had a median
survival of 5.4, 11.7, and 32.9 months, respectively.Conclusion:Patients with either a synchronous or latent diagnosis of RCC survived
greater than 6 months from the time of presentation. Initial Furhman grade,
Tokuhashi score, and MSKCC/Motzer can be useful tools in informing
patient-specific prognosis for those with metastatic RCC of the spine.